Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: An open dose-range study

Pharmacopsychiatry

Volumn 29, Issue 2, 1996, Pages 63-66

  Modell, S ^a   Naber, D ^a,b   Holzbach, R ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ELIPRODIL; OPIATE ANTAGONIST; OPIATE RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEADACHE; HUMAN; MALE; MENTAL DISEASE; NAUSEA; NEGATIVE SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0029918017     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979546     Document Type: Article

References (24)

1. Andree, T. H., T. Feodora, K. Climi, M. Abou-Gharbia, E. A. Muth: Neurochemical profile of the potential antipsychotic compound WY-47,384. Soc. Neurosci. Abstr. 12 (1986) 477
2. Chouinard, G., L. Annable: An early phase II clinical trial of BW 234U in the treatment of acute schizophrenia in newly admitted patients. Psychopharmacology 84 (1984) 282-284
3. Clissold, D. B., M. J. Pontecorvo, B. E. Jones, M. E. Abreu, E. W. Karbon, R. H. Erickson, K. J. Natalie Jr., S. Borosky, T. Hartman, R. S. Mansbach, R. L. Balster, J. W. Ferkany, S. J. Enna: NPC 16377, a potent and selective sigma-ligand. II. Behavioral and neuroprotective profile. J. Pharmacol. Exp. Ther. 265 (1992) 876-886
4. Davidson, J., R. Miller, M. Wingfield, W. Zung, A. T. Dren: The first clinical study of BW 234U in schizophrenia. Psychopharm. Bull. 18 (1982) 173-176
5. Davidson, J., R. Miller, P. Manberg, C. Kilts, M. Wingfield: BW 234: a nondopamine receptor blocking antipsychotic drug without extrapyramidal side effects? Drug Dev. Res. 6 (1985) 13-17
6. Deutch, S. I., A. Weizman, M. E. Goldman, J. M. Morihisa: The sigma receptor: a novel site implicated in psychosis and antipsychotic drug efficacy. Clin. Neuropharmacol. 11 (1988) 105-119
7. Guy, W., G. Manov, W. H. Wilson, T. A. Ban, O. K. Fjetland, P. J. Manberg, A. T. Dren: Psychotropic actions of BW 234U in the treatment of inpatient schizophrenics: a dose range study. Drug Dev. Res. 3 (1983) 245-252
8. Jain, A. K., S. Kelwala, N. Moore, S. Gershon: A controlled clinical trial of tiosperone in schizophrenia. Int. Clin. Psychopharmacol. 2 (1987) 129-135
9. Largent, B. L., H. Wikström, A. M. Snowman, S. H. Snyder: Novel antipsychotic drugs share high affinity for sigma receptors. Eur. J. Pharmacol. 155 (1988) 345-347
10. Lieberman, J. A.: Understanding the mechanisms of action of atypical antipsychotic drugs. A review of compounds in use and development. Br. J. Psychiatry 163 (suppl. 22) (1993) 7-18
11. McLean, S., E. Weber: Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea pig brain. Neuroscience 25 (1988) 259-269
12. Pfeiffer, A., V. Brante, A. Herz, H. M. Emrich: Psychotomimetics mediated by opiate receptors. Science 233 (1986) 774-776
13. Seeman, P.: Dopamine receptors and the dopamine hypothesis of schizophrenia. Eur. J. Pharmacol. 1 (1987) 133-152
14. Simpson, M. D. C., P. Slater, M. C. Royston, J. F. W. Deakin: Alterations in phencyclidine and sigma binding sites in schizophrenic brains: Effects of disease process and neuroleptic medication. Schizophr. Res. 6 (1992) 41-48
15. Stevens, J. R.: An anatomy of schizophrenia? Arch. Gen. Psychiatry 29 (1973) 177-189
16. 3H)SKF-10047 to etorphine inaccessible sites in guinea pig brain. J. Pharmacol. Exp. Ther. 223 (1982) 284-290
17. 2 receptors and sigma-receptors in the brain. Neurosci. Lett. 71 (1986) 224-228
18. Schwarcz, G., A. Halaris, A. Dren, P. Manberg: Open label evaluation of the novel antipsychotic compound BW 234U in chronic schizophrenics. Drug Dev. Res. 5 (1985) 387-393
19. 3H]haloperidol binding in guinea pig brain membranes. Proc. Natl. Sci. USA 81 (1984) 5618-5621
20. Tam, S. W., A.-Z. Zhang: Sigma and PCP receptors in human frontal cortex membranes. Eur. J. Pharmacol. 154 (1988) 343-344
21. Taylor, D. P., J. Dekleva: Potential antipsychotic BMY 14802 selectively binds to sigma sites. Drug Dev. Res. 11 (1987) 65-70
22. Taylor, D. P., J. Dekleva: BMY 14802: A potential antipsychotic agent that selectively binds to sigma receptors. In: Domino, E. F., J.-M. Kamanka (eds.): Sigma and phencyclidine-like compounds as molecular probes in biology, NPP books, Ann Arbor, MI (1988) 345
23. Weinberger, D. R.: Schizophrenia and the frontal lobe. Trends Neurosci. 11 (1988) 367-370
24. Weisman, A. D., T. P. Su, J. C. Hedreen, E. D. London: Sigma receptors in postmortem human brains. J. Pharmacol. Exp. Ther. 247 (1988) 29-33